タバタ　ツトム   TABATA Tsutomu   田畑　務    所属   医学部 医学科（東京女子医科大学病院）    職種   教授・基幹分野長
論文種別	その他
言語種別	英語
査読の有無	査読あり
表題	Quality of care measurement for patients with ovarian cancer in Japan.
掲載誌名	正式名：The journal of obstetrics and gynaecology research 略　 称：J Obstet Gynaecol Res ISSNコード：14470756/13418076
掲載区分	国外
巻・号・頁	50(7),pp.1182-1191
著者・共著者	Kakuwa Tamaki, Watanabe Tomone, Niino Mariko, Kawata Akira, Satoh Toyomi, Matsumura Noriomi, Yokoyama Yoshihito, Kawana Kei, Hirashima Yasuyuki, Kyo Satoru, Yasuda Masanori, Harano Kenichi, Machida Hiroko, Tokunaga Hideki, Kaneuchi Masanori, Tabata Tsutomu, Kobayashi Yoichi, Nagase Satoru, Katabuchi Hidetaka, Mikami Mikio, Yamamoto Yoko, Rikitake Ryoko, Ichinose Yuichi, Higashi Takahiro
担当区分	責任著者
発行年月	2024/07
概要	AIM:Quality of care is important to reduce disease progression, and improve both survival and quality of life. The Japan Society of Gynecologic Oncology has published treatment guidelines to promote standardized high-quality care for ovarian cancer in Japan. We developed quality indicators based on the guideline recommendations and used them on large datasets of health service use to examine the quality of ovarian cancer care.METHODS:A panel of experts developed the indicators using a modified Delphi method. Adherence to each indicator was evaluated using data from a hospital-based cancer registry of patients diagnosed in 2018. All patients receiving first-line treatment at participating facilities were included. The adherence rates were returned to participating hospitals, and reasons for nonadherence were collected. A total of 580 hospitals participated, and the study examined the care received by 6611 patients with ovarian cancer and 1879 with borderline tumors using 11 measurable quality indicators.RESULTS:The adherence rate ranged from 22.6% for "Estrogen replacement within 6 months of operation" to 93.5% for "Bleomycin, etoposide, and cisplatin for germ cell tumor more than Stage II." Of 580 hospitals, 184 submitted the reasons for nonadherence.CONCLUSIONS:The quality of ovarian cancer care should be continuously assessed to encourage the use of best practices. These indicators may be a useful tool for this purpose.
DOI	10.1111/jog.15961
PMID	38697202